Cognition Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	13.53	13.23	10.03	4.52	3.45
Research & Development	37.2	30.32	18.57	12.89	14.38
Operating Expenses	50.72	43.55	28.6	17.41	17.83
Operating Income	-50.72	-43.55	-28.6	-17.41	-17.83
Interest Expense / Income	0.03	0.03	0.89	1.75	1.02
Other Expense / Income	-24.96	-22.18	-17.78	-11.32	-14.01
Pretax Income	-25.79	-21.4	-11.72	-7.84	-4.84
Net Income	-25.79	-21.4	-11.72	-7.84	-4.84
Preferred Dividends	0	0	4.53	4.23	3.92
Net Income Common	-25.79	-21.4	-16.25	-12.07	-8.76
Shares Outstanding (Basic)	30	24	5	1	2
Shares Outstanding (Diluted)	30	24	5	1	2
Shares Change	27.03%	355.42%	921.60%	-66.56%	-
EPS (Basic)	-0.86	-0.91	-3.13	-23.76	-5.77
EPS (Diluted)	-0.86	-0.91	-3.13	-23.76	-5.77
Free Cash Flow	-16.17	-18.7	-3.66	-3.44	-3.24
Free Cash Flow Per Share	-0.54	-0.79	-0.70	-6.78	-2.13
EBITDA	-25.51	-21.13	-10.73	-5.99	-3.74
Depreciation & Amortization	0.25	0.24	0.09	0.1	0.08
EBIT	-25.76	-21.37	-10.82	-6.09	-3.82

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).